

#10

Page Number

REQUEST FOR ACCESS

二

8/01/95

RECEPTIONIST REVIEWED

SERIAL NUMBER

904.662

AUG 01 1995

ESTATE PLANNING

Sept. 8 1992

GROUP 1800

卷之三

THE UNDERSIGNED HEREBY RESPECTFULLY REQUESTS ACCESS TO THE PCT HISTORY OF THE FOLLOWING ABANDONED APPLICATION WHICH WAS REFERRED TO IN U.S. PATENT NUMBER 5399346 OR PARENT APPLICATION

RESPECTUOUSLY YOURS,

Joseph A. Lucas

OPTIONAL USE ONLY

Initials
File Information Unit

74

2



US05399346A

United States Patent [19]

Anderson et al.

[11] Patent Number: 5,399,346

[45] Date of Patent: Mar. 21, 1995

[54] GENE THERAPY

[75] Inventors: W. French Anderson, Bethesda; R. Michael Blaese, Rockville; Steven A. Rosenberg, Bethesda, all of Md.

[73] Assignee: The United States of America as represented by the Department of Health and Human Services, Washington, D.C.

[21] Appl. No.: 220,175

[22] Filed: Mar. 30, 1994

Related U.S. Application Data

[63] Continuation of Ser. No. 904,662, Sep. 8, 1992, abandoned, which is a continuation-in-part of Ser. No. 868,794, Apr. 15, 1992, abandoned, which is a continuation-in-part of Ser. No. 807,446, Dec. 13, 1991, abandoned, which is a continuation-in-part of Ser. No. 365,567, Jun. 14, 1989, abandoned.

[51] Int. Cl. 6 A61K 48/00; C12N 5/22; C12N 15/63; C12N 15/09

[52] U.S. Cl. 424/93.21; 435/172.3; 435/240.2; 435/69.5; 435/69.51; 435/69.52; 935/62; 935/22; 935/32; 935/34; 935/57; 935/79

[58] Field of Search 935/22, 32, 34, 57, 935/62, 79; 435/172.3, 240.2, 69.5, 69.51, 69.52; 424/93.21

[56]

References Cited

PUBLICATIONS

Siegel, Los Angeles Times, Dec. 14, 1987, "Desire to be First Colors Gene Studies" pp. 1,22-25.

Buden, The Scientist, Jan. 23, 1989, "Controversy Surrounds Gene Therapy Effort", pp. 1-3.

Siegel, Los Angeles Times, Dec. 13, 1987, "Egos, Prizes on the Line for Scientists", pp. 1, 17-40.

Anderson, John W., The Nation, Apr. 10, 1989, "Scrambling for Biotech Bucks", pp. 476-478.

Selden, N. Eng. J. Med., vol. 318, No. 20, pp. 1337-1338.

Thompson, Time, Jun. 7, 1993 "The First Kids With New Gene" pp. 50-53.

Primary Examiner—Jacqueline Stone

Attorney, Agent, or Firm—Elliot M. Olstein; Raymond J. Lillie

[57]

ABSTRACT

Primary human cells which are genetically engineered with DNA (RNA) encoding a marker or therapeutic which is expressed to be expressed in vivo. Such engineered cells may be used in gene therapy.

14 Claims, 6 Drawing Sheets

95

28